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Abstract 
Parathyroid hormone-related protein (PTHrP) inhibits proliferation of several lung cancer cell lines, but the signaling 
mechanism has not been established. This study tested the hypotheses that growth inhibition is mediated through 
the PTHrP receptor, PTH1R, and that the process is modified by ERK activation. PTHrP-positive and negative clones of 
H1944 lung adenocarcinoma cells underwent stable PTH1R knockdown with lentiviral shRNA or transient transfection 
with ERK1 and ERK2 siRNA. Alternatively, cells were treated with 8-CPT cAMP, 8-CPT 2′-O-methyl cAMP, and N-6-phenyl 
cAMP analogs. H1944 cells expressing ectopic PTHrP showed 20–40% decrease in proliferation compared to the PTHrP-
negative cells in the presence of normal levels of PTH1R (P < 0.01). PTH1R knockdown eliminated this difference and 
increased cell proliferation regardless of PTHrP status. The three cAMP analogs each inhibited proliferation over 5 days 
by 30–40%. ERK2 knockdown inhibited proliferation of PTHrP-positive cells alone and in combination with ERK1 knock-
down. The growth inhibition mediated by cAMP analogs was unaffected by ERK1 knockdown. In conclusion, ectopic 
expression of PTHrP 1–87 inhibits H1944 cell proliferation. PTH1R knockdown blocks this effect and stimulates prolif-
eration, indicating that the ligand exerts anti-mitogenic effects. cAMP, the second messenger for PTH1R also inhibits 
proliferation and activates ERK. PTHrP growth inhibition may be opposed by concomitant ERK activation.
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Background
The amino-terminal region of parathyroid hormone-
related protein (PTHrP), residues 1–34, shares structural 
and functional features with the same region of parathy-
roid hormone (PTH). Thus, PTHrP 1–34 and PTH 1–34 
activate the same G protein-coupled receptor, PTH1R. 
Furthermore, PTHrP causes the same effects with simi-
lar potency compared to PTH when the receptor is 
ligated (Abou-Samra et  al. 1992). In lung cancer, amino 
PTHrP–PTH1R interactions are most frequently recog-
nized in the syndrome of hypercalcemia of malignancy 
(Suva et  al. 1987). Mid-molecule PTHrP peptides (resi-
dues 38–94) and carboxyl-terminal PTHrP peptides (res-
idues 107–141) have biologic activities that are unique 
from the effects of PTHrP 1–34 (Orloff et al. 1994). For 
example, mid-molecule PTHrP fragments can regulate 
growth in breast cancer cells (Luparello et al. 2001), while 
the carboxyl domain affects function and proliferation in 
osteoclasts (Zheng et al. 1994). The non-amino effects of 
PTHrP are also presumed to result from binding to other 
cell-surface receptors, but such receptors have yet to be 
discovered (Orloff et  al. 1994). In addition to cell sur-
face actions, PTHrP can localize to the nucleus and can 
exert intracrine effects inside the cell (Gujral et al. 2001). 
Interestingly, the intracrine effects of PTHrP stimulate 
growth of vascular smooth muscle cells, in opposition to 
the anti-mitogenic receptor-mediated effects of PTHrP 
1–34 (Stuart et  al. 2000). Consequently, a variety of 
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possible mechanisms must be considered to understand 
the effects of PTHrP in a given tissue or cell type.
PTHrP is expressed in two-thirds of human non-small 
cell lung carcinomas (NSCLC) (Hastings et al. 2006). In a 
previous study, we used an expression plasmid to evalu-
ate the proliferative effects of amino PTHrP in H1944 
lung adenocarcinoma cells and MV522 lung adenocarci-
noma cells, two lines which possess PTH1R but normally 
do not express PTHrP (Hastings et  al. 2009). A vector 
for PTHrP 1–87 was employed in this study because 
plasmids with shorter coding sequences function poorly 
for expressing the target protein (Ditmer et  al. 1996). 
In both H1944 cells and MV522 cells, introduction of 
PTHrP resulted in slower increases in cell numbers and 
decreased incorporation of thymidine or BrdU into cel-
lular DNA, but no apoptosis. This constellation of effects 
pointed toward changes in proliferation. The growth 
inhibition could be mediated by PTH1R or by a recep-
tor for mid-molecule PTHrP, since PTHrP 1–87 includes 
both amino and mid-molecule sequences. Some inves-
tigators have suggested that PTHrP 1–87 can also cause 
intracrine signaling (Gujral et  al. 2001), so this might 
be another mechanism regulating proliferation. PTHrP 
1–87 transfection also stimulated phosphorylation of 
extracellular signal-regulated kinase (ERK). ERK signal-
ing is generally associated with a proliferative response 
(Gollob et  al. 2006), but prolonged activation of the 
pathway mediates cell cycle arrest in cells derived from 
a variety of benign and malignant tissues, including lung 
cancer (Wen-Sheng 2006; Clark et al. 2004; Sriuranpong 
et al. 2001). It is unknown what role ERK plays, if any, in 
PTHrP-dependent growth inhibition in lung cancer cells 
(Hastings et al. 2009).
The goal of this study was to establish the upstream 
mechanism through which PTHrP regulates lung can-
cer cell proliferation and to determine whether ERK is 
involved in the downstream signaling. We hypothesized 
that PTHrP activated ERK through PTH1R, leading to 
the inhibitory effects on proliferation. We used genetic 
approaches to alter PTH1R expression and ERK activity 
in H1944 cell clones that had been transfected with an 
expression plasmid for PTHrP 1–87 or with the empty 
vector to answer these questions.
Methods
Cell culture
NCI-H1944 human lung adenocarcinoma cells were 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). The cells were grown in 
a humidified incubator with 5% CO2/95% oxygen and 
in RPMI 1640 medium plus 8% fetal bovine serum sup-
plemented with d-glucose, HEPES, sodium bicarbo-
nate and sodium pyruvate. Prior to growth experiments, 
cells were incubated in serum-free medium with 1  mg/
ml bovine serum albumin for 24-h to synchronize their 
growth cycle. Wild type H1944 cells do not make PTHrP. 
PTHrP-expressing H1944 cell clones produced by sta-
ble transfection make significant quantities of PTHrP, as 
determined by immunoassay (Hastings et al. 2009).
Lentiviral shRNA knockdown of PTH1R
MISSION® shRNA transduction-ready lentiviral particles 
directed against PTH1R promoter were obtained from 
Sigma-Aldrich Chemical (St. Louis, MO, USA). H1944 
cells were seeded at 70–80% confluency in 48 well cell 
culture plates. The next day, the cells were transferred 
into fresh media containing 8 µl/ml hexadimethrine bro-
mide and shRNA particles at 15 multiplicity of infection 
(MOI), which had been determined as optimum in pre-
liminary trials. The shRNA particles were removed after 
another 24  h and replaced with fresh media containing 
2 µg/ml of Puromycin. Stable clones were selected from 
colonies that survived exposure to a titrated lethal dose 
of puromycin antibiotic after several passages. Long-
term inhibition of PTH1R expression in H1944 cells was 
assessed by immunoblotting. Control clones were stably 
transduced with non-target control (NTC) particles from 
Sigma.
ERK siRNA transfections
H1944 PTHrP positive and negative cells were seeded at 
2.5 × 105 cells/well in 6-well plates to 40–50% confluency 
and transiently transfected with siRNA oligonucleotides 
that targeted ERK1 and ERK2 or non-silencing control 
sequences (sc-44205, sc-35335, and sc-37007, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Each transfection 
used 20  pmol of siRNA oligomer in 500  µl serum-free 
RPMI mixed with 3  µl Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA). Cells were transfected for 48  h 
at 37°C in 1.5  ml of growth medium, then washed and 
returned to growth medium with 1 mg/ml bovine serum 
albumin substituted for serum for 24 h before beginning 
an experimental protocol. Efficiency of siRNA transfec-
tion was assessed by Western blot.
Western blots
Protein was extracted from cell pellets in lysis buffer with 
phosphatase inhibitors (20 mM Tris–HCl, 150 mM NaCl, 
1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM Na3VO4, 1 µM PMSF, 1× 
NaF and 1 µg/ml leupeptin). Complete lysis was ensured 
by exposing cells to a freeze–thaw cycle followed by soni-
cation and vortexing. Lysates were cleared by centrifuga-
tion. Total protein concentrations were measured using 
a BCA assay (Pierce, Rockford, IL, USA). Wells in Crite-
rion™ 4–12% Bis–Tris gels (Bio-Rad, Hercules, CA, USA) 
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were loaded with 10  µg protein samples, separated by 
electrophoresis and transferred to polyvinylidene fluoride 
membranes. Membranes were blocked with 3% bovine 
serum albumin or 5% non-fat milk for 90  min at room 
temperature and probed with primary antibodies over-
night at 4°C. Antibodies were directed against PTH1R 
(PRB-640P, Covance, San Diego, CA, USA), β-Tubulin, 
p-ERK (E-4) and ERK1 (K-23) (Santa Cruz Biotechnol-
ogy), and p-Akt (serine 473) and total Akt. The epitope 
for the p-ERK antibody was a conserved sequence pre-
sent in both ERK1 and ERK2 that contains a phospho-
rylated tyrosine, tyr 204 in ERK1. The ERK1 antibody 
recognizes a sequence within the XI subdomain in both 
phosphorylated and unphosphorylated forms of ERK1 
and ERK2. After incubation with primary antibody, blots 
were then exposed to goat anti-mouse (sc-2031) or goat 
anti-rabbit (sc-2030) IgG-HRP conjugated secondary 
antibodies for 0.5–1 h at room temperature. Chemilumi-
nescence was elicited by treatment with Amersham ECL 
Plus Western Blotting Detection Reagents (GE Health-
care) and recorded with the UVP BioSpectrum 410 
imaging system (Upland, CA, USA). Band densities were 
analyzed with VisionWorksLS Analysis Software (UVP).
PTHrP quantitative polymerase chain reaction (qPCR)
RNA was isolated from replicates of three cell culture 
wells each from H1944 cells, H358 lung adenocarci-
noma cells and H441 lung adenocarcinoma cells with 
a mini kit (Qiagen, Valencia, CA, USA). The H358 cells 
and H441 cells are known to produce moderate levels 
of PTHrP. RNA was incubated with Moloney Murine 
Leukemia Virus reverse transcriptase (Invitrogen, Carls-
bad, CA, USA) to produce cDNA for template. QPCR 
was performed on an ABI Prism 7000 real time PCR 
machine as previously described (Hastings et  al. 2010) 
to amplify sequences from the PTHrP coding region and 
from β-actin. Relative abundance of PTHrP mRNA was 
calculated with β-actin as reference gene and H358 cells 
as the comparator by the Pfaffl method. Primers were 
forward 5′-CTGACACCTCCACAACGTCG-3′, reverse 
5′-AGAATCCTGCAATATGTCCTTGG-3′ for PTHrP, 
and forward 5′-CCGAGGACTTTGATTGCACAT-3′ 
and reverse 5′-TTAGGATGGCAAGGGACTTCC-3′ for 
β-actin.
MTS cell proliferation assay
Cells were plated at 1,500–2,500  cells/well in 96-well 
plates in growth media with FBS for proper cell adher-
ence. In each experiment, cells were monitored by 
phase contrast microscopy to assess attachment and 
overall health. Assays in separate plates were stopped 
at 0–5  days after plating. The quantity of viable cells 
was assessed with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS) compound (Promega, Madison, WI, USA) 
after 1 h incubation at 37°C. MTS is bioreduced by meta-
bolically active cells into a colored formazan product sol-
uble in tissue culture media, which can be read at 490 nm 
absorbance. The absorbance is directly proportional to 
the number of living cells. In every experiment, a stand-
ard curve was constructed for each line relating absorb-
ance to cell number. Results were analyzed in terms of 
cell number.
In some experiments, cells were treated at 
the start of the growth period with 1–200  µM 
8-(4-chlorophenyl th io)-adeno s ine-3 ′ , 5 ′ -c yc l ic 
monophosphate (8-CPT-cAMP), 8-CPT-2′-O-methyl-
cAMP (me-cAMP), or N-6-phenyl-cAMP (phe-cAMP). 
8-CPT-cAMP is a non-selective agonist, while me-cAMP 





Studies utilized three H1944 cell clones that make 600–
700 pg PTHrP 1–34/µg cell protein/24 h as a result of sta-
ble transfection with the PTHrP 1–87 expression plasmid 
(Hastings et al. 2009). Cells from these clones were trans-
duced with PTH1R shRNA particles or NTC particles 
to generate three PTHrP-positive, PTH1R knockdown 
clones and three clones with intact PTH1R. PTH1R levels 
in the knockdown clones were 30–45% of levels present 
in cells stably transduced with NTC shRNA (Figure 1a). 
By MTS assay, the PTH1R knockdown cells nearly tripled 
in number over a 2 days period, a 37 ± 1% faster growth 
rate when compared to the NTC-transfected cells, which 
only doubled in number over the same period (Figure 1b, 
P < 0.01). In comparison, wild type PTHrP-negative cells 
increased their numbers over 2 days by roughly 2.5-fold 
when PTH1R was intact and by about 3-fold when the 
receptor was knocked down (for example, see open bars 
at day 2 in Figure 1e). Thus, PTH1R knockdown reversed 
the growth inhibition induced by ectopic expression 
of PTHrP 1–87 and restored the rate of proliferation 
to levels close to those in PTHrP-null cells. These find-
ings indicate that the presence of PTH1R suppresses cell 
replication.
Additional experiments evaluated the role of PTH1R 
in response to cell surface exposure to exogenous PTHrP. 
Exogenous PTHrP inhibited wild type H1944 cell growth 
in dose-dependent fashion (Figure 1c), as we have reported 
previously (Hastings et al. 2009). Wild type, PTHrP-nega-
tive H1944 cells underwent PTH1R knockdown to develop 
two independent knockdown clones along with two NTC 
clones. PTH1R knockdown clones differed from NTC 
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clones in PTH1R level by 75–90% (Figure 1d). In the clones 
with intact PTH1R, treatment with the highest concentra-
tion of PTHrP 1–34 from the dose response experiment, 
100 nM, decreased cell growth by 25 and 50% at days 1 and 
2, respectively, compared to treatment with vehicle with-
out PTHrP. However, exogenous PTHrP had no effect on 
the PTH1R knockdown clones (Figure  1e). Interestingly, 
PTH1R knockdown increased cell growth by roughly 60% 
compared to NTC controls in the absence of measur-
able PTHrP 1–34 (P < 0.001). This can be appreciated in 
Figure 1e by comparing the open bars between the knock-
down and NTC groups. These data are consistent with 
two alternative explanations. Either the receptor possesses 
constitutive activity independent of ligand or that H1944 
cells express levels of PTHrP 1–34 below the assay detec-
tion limit that still affect cell growth. qPCR assays indi-
cate that H1944 cells contain quantifiable levels of PTHrP 
mRNA (Table 1), roughly 5–10% of the quantities in H358 
cells and H441 cells. Given the presence of mRNA, H1944 
cells could also be making low levels of PTHrP protein.
cAMP effect
Since PTH1R stimulates cAMP as its second messen-
ger in H1944 cells (Hastings et  al. 2009) and BEN lung 
cancer cells (Hastings et  al. 2004; Kukreja et  al. 1988; 
Pizurki et  al. 1988), we investigated the direct effects of 
cell-permeant cAMP compounds on H1944 cell growth. 
8-CPT-cAMP, a non-selective analog, inhibited the rise 
Figure 1 Effect of PTH1R knockdown on H1944 proliferation. a Stable transduction of PTHrP-positive cells with shRNA lentiviral particles directed 
against PTH1R (open bars) resulted in 55–70% knockdown of the protein compared to levels in cells transduced with NTC particles (closed grey 
bar). b The PTH1R knockdown clones demonstrated increased proliferation (open circles) measured by MTS assay compared to NTC clones (closed 
circles). N = 3 clones for each group. Error bars are smaller than the symbol for some points and may not be visible. **P < 0.01 vs. NTC cells at each 
time point. c Treatment with exogenous PTHrP 1–34 for 1–5 days decreased H1944 cell proliferation in a dose-dependent fashion. The six columns 
at each time point represent increasing PTHrP concentrations of 0, 10−11, 10−10, 10−9, 10−8, and 10−7 M. The reduction at the largest dose of 10−7 M 
was about 25%. Data are replicates of 8 cell wells per day and PTHrP concentration. Similar results were obtained in multiple independent experi-
ments (§P < 0.001). d In PTHrP-null H1944 cells, stable shRNA transduction resulted in 75–90% knockdown of PTH1R (open bars) compared to levels 
in NTC control clones (grey bars). e When PTH1R was intact (NTC group), treatment with exogenous 100 nM PTHrP 1–34 (closed grey bars) inhibited 
proliferation of wild type H1944 cells by 25–50% compared to cells treated with the PTHrP vehicle (open bars) (§P < 0.001). However, exogenous 
PTHrP 1–34 had no effect on growth rate in clones after stable knockdown of PTH1R. Comparison of the open bars between PTH1R knockdown 
clones and NTC clones demonstrates that reduction in PTH1R expression increased proliferation even in the absence of exogenous PTHrP 1–34. 
§P < 0.001.
Table 1 PTHrP mRNA expression in human lung adenocar-
cinoma cell lines
Values are avg ± SE unless otherwise indicated.
ΔCT values for β-actin ranged from 14.6 ± 0.6 to 15. 1 ± 0.2 for the three cell 
lines.







H358 6 23.6 ± 0.6 8.8 ± 0.6 0.0 ± 0.1 1.00 (0.92–1.08)
H441 6 24.5 ± 0.1 9.9 ± 0.1 −1.0 ± 0.1 0.50 (0.45–0.54)
H1944 5 27.9 ± 0.3 13.0 ± 0.2 −4.2 ± 0.2 0.05 (0.04–0.07)
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in cell number in a time- and dose-dependent manner 
(Figure  2a, b). At a concentration of 200  µM, 8-CPT-
cAMP reduced growth over 5  days by about 35%. Cells 
treated with 200 µM 8-CPT-cAMP for 4–6 days did not 
differ in their ability to exclude trypan blue compared 
to untreated cells, ensuring that the observed effect was 
due to growth inhibition, as opposed to cell death. Via-
bility for treated and untreated cells was 92.6 ±  1.4 vs. 
87.7 ±  3.9%, respectively after 3  days of treatment, and 
92.0 ± 1.0 vs. 91.5 ± 1.0%, respectively after 5 days, with 
n = 6 replicates per group.
The growth inhibitory effects were not linked specifi-
cally to PKA or EPAC. N6-phe-cAMP, the PKA specific 
analog, and me-cAMP, the analog targeting EPAC, both 
inhibited H1944 cell growth (Figure 2c). At 200 µM, phe-
cAMP reduced H1944 growth by 39  ±  2% (P  <  0.001 
vs. untreated cells), while the inhibition with 200  µM 
me-cAMP was 23 ± 3% (P < 0.001 vs. no treatment). By 
two-way ANOVA, growth inhibition depended on con-
centration (P < 0.0001) but did not vary between the two 
analogs (P = 0.37).
The cAMP analogs inhibited growth of the H1944 
clones with PTH1R knockdown (Figure 2d) and the effect 
was similar in magnitude to the effect in cells with intact 
PTH1R expression. Thus, PTH1R knockdown prevented 
the anti-proliferative effect following treatment with 
PTHrP 1–34 (Figure 1b, e), but did not alter the inhibi-
tory influence of cAMP (Figure 2d).
Role of ERK activation
PTHrP effects on ERK
Similar to our 2009 findings (Hastings et  al. 2009), 
PTHrP-positive H1944 cells demonstrated pERK1 and 
pERK2 levels roughly twice as great as those in PTHrP-
negative cells (Figure  3a). Total ERK protein expression 
was not altered significantly by PTHrP, based on immu-
noblotting. The level of pERK2 was roughly 4 times 
greater than the level of pERK1 in H1944 cells. In con-
trast to ERK, PTHrP expression did not activate Akt 
(Figure 3b).
ERK2 knockdown and PTHrP‑mediated growth inhibition
Transient transfection with ERK2 siRNA constructs 
resulted in 70–80% reduction in ERK2 expression in 
both PTHrP-positive and negative H1944 cells that per-
sisted at least 72 h after treatment (Figure 4a). The ERK2 
knockdown had no apparent effect on ERK1, and control, 
non-silencing oligonucleotides had no effect on either 
ERK species.
ERK2 knockdown reduced the rate of growth in MTS 
assays of three out of four independent PTHrP-express-
ing H1944 cell clones (Figure  4b). The reduction was 
significant, based on paired t test, at 24 h and later time 
points. At 72  h, proliferation was reduced by an aver-
age of 20.5  ±  3.4% in the three clones that responded 
to ERK2 knockdown. In contrast to the PTHrP-positive 
cells, knockdown of ERK2 in PTHrP-negative cells did 
not have a consistent or significant effect on cell prolif-
eration (Figure 4b).
ERK1 knockdown and PTHrP‑mediated growth inhibition
Transfection with ERK1 siRNA decreased ERK1 protein 
by 70–80% for 72 h (Figure 5a), but also led to increased 
expression of ERK2 protein. Levels of ERK2 increased by 
almost four-fold over the 3-day period.
Cells from PTHrP positive clones grew at the same 
rate after ERK1 knockdown as cells transfected with 
the control siRNA for the first 48  h, then showed a 
small 10% increase in cell number at 72  h (Figure  5b, 
left panel). ERK1 knockdown did not affect growth 
Figure 2 cAMP in PTH1R signaling and proliferation effects. a 8-CPT-cAMP attenuated the growth of H1944 cell number in a time- and dose-
dependent fashion. Open diamonds, grey squares and black triangles represent cells left untreated or exposed to 100 and 200 µM 8-CPT-cAMP, 
respectively (n = 3 independent experiments, 6 replicates per experiment) *P < 0.05. b Increasing 8-CPT cAMP concentration caused progressively 
greater changes in cell number at day 5 with significant differences at 100 and 200 µM. *P < 0.05 and **P < 0.01 vs. untreated cells. c N-6-phenyl-
cAMP (phe-cAMP), a cAMP analog targeting protein kinase A, and 8-CPT-2-O′-methyl-8-cAMP (me-cAMP), an EPAC-specific analog, both attenuated 
rate of increase in H1944 cell number over 5 days. Graph shows cell numbers at day 5. Concentrations range from 0 to 200 µM, as in panel  
b. **P < 0.01, §P < 0.001 vs. untreated cells. d phe-cAMP and me-cAMP retained their growth inhibitory effects regardless of PTH1R expression. 
The figure shows results for PTH1R-expressing NTC clones (PTH1R+) and PTH1R knockdown clones (PTH1R−). Cell number is expressed relative to 
untreated PTH1R-positive cells. §P < 0.001 vs. cells not treated with cAMP analog.
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rate in PTHrP-negative H1944 clones (Figure 5b, right 
panel).
Combined ERK1/ERK2 knockdown
To avoid the confounding influence of ERK2 upregula-
tion, we combined the siRNA treatments to knock down 
both isoforms. ERK1 plus ERK2 knockdown decreased 
both pERK1 and pERK2 levels over 72  h. The reduc-
tion in pERK1 ranged from 20 to 50% knockdown, while 
pERK2 decreased by 50–75%, depending on the elapsed 
time after the transfection. Both ERK siRNAs gradually 
lost their knockdown efficiency over time, but pERK lev-
els were still reduced compared to the control siRNA at 
72 h (Figure 6a).
Figure 3 Kinase activation by PTHrP. a PTHrP-positive H1944 clones demonstrated increased levels of phosphorylated extracellular signal-regulated 
kinase (pERK) compared to the PTHrP-negative vector controls. Blots were performed multiple times with reproducible results. **P < 0.01 vs. vector 
control. b Ectopic PTHrP expression had no effect on Akt phosphorylation in H1944 cells. The figure shows immunoblots from 4 PTHrP-negative, 
vector-transfected H1944 cell clones and 5 independent PTHrP-positive clones.
Figure 4 ERK2 knockdown and H1944 cell proliferation. a ERK2 siRNA (closed bars) knocked down expression of the target by 70–80% compared 
to NTC siRNA (open bars). The effect lasted at least 72 h. ERK1 was not affected by ERK2 knockdown. b H1944 cell proliferation was measured by 
MTS assay in 4 clones of PTHrP-positive cells and 3 clones of PTHrP-negative cells for 0–72 h after transient transfection with ERK2 siRNA or NTC 
oligonucleotides. The line segments in the upper graph connect points with and without ERK2 knockdown for the same clone and time point. ERK2 
knockdown reduced proliferation over 72 h in 3 out of 4 PTHrP-positive H1944 cell clones. In contrast, ERK2 knockdown had no significant effect 
on proliferation in three PTHrP-negative clones. The lower graph presents averages ± standard errors, with open bars and closed bars representing 
transfection with NTC siRNA and ERK2 siRNA, respectively. Data were analyzed by paired t test comparing the effects of knockdown at a given time 
point between cells from the same clone. *P < 0.05, **P < 0.01 for NTC vs. ERK2 knockdown.
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The dual ERK knockdown significantly decreased pro-
liferation of PTHrP positive cells by 25% at 72  h post 
transfection but had no apparent effect at 24 and 48  h 
(Figure  6b). This finding was interesting because the 
extent of ERK2 knockdown at 72 h was less than it was at 
the 24 and 48 h time points (Figure 6a). Combined ERK1 
and ERK2 siRNA knockdown did not cause any signifi-
cant changes in the proliferation of PTHrP negative cells 
over 72 h.
Effect of cAMP after ERK1 knockdown
Since ERK1 knockdown stimulated proliferation, we 
investigated whether the reduction in ERK1 would alter 
cAMP-mediated growth inhibition. Treatment with 
cAMP analogs inhibited H1944 cell growth by 30–60%, 
even after 50% knockdown of ERK1. The anti-prolifera-
tive effect was similar to that observed when ERK1 levels 
were not manipulated (Figure  7), suggesting that ERK1 
phosphorylation does not contribute in a major way to 
the suppression of cell division caused by cAMP.
Discussion
In earlier work, we found that stable transfection of 
PTHrP 1–87 into PTHrP-negative lung adenocarcinoma 
cells inhibited proliferation (Hastings et  al. 2009). The 
antimitogenic effects were associated with decreased 
expression of cyclin D2 and cyclin A2, increased expres-
sion of p27Kip and decreased activation of cdk2. 
Figure 5 ERK1 knockdown and H1944 cell proliferation. a Transfection with ERK1 siRNA achieved 70–80% knockdown of ERK1 but also stimulated 
expression of ERK2. The bottom panel shows that the changes in ERK1 (open bars) and ERK2 (grey bars) lasted at least 72 h. b On the whole, transfec-
tion with ERK1 antisense constructs did not have a substantial effect on growth in four independent clones of PTHrP-positive cells or three clones 
of PTHrP negative cells. The formatting is similar to Figure 4, with line segments linking points from the same H1944 cell clone. ERK1 knockdown 
(closed, black bars in the bottom graph, panel b) resulted in a slight increase in cell number at 72 h compared to NTC siRNA treatment (open bars in 
panel b) in the PTHrP-positive cells. *P < 0.05 vs. control NTC siRNA by paired t test.
Figure 6 Combined ERK1 and ERK2 siRNA knockdown vs. proliferation. a H1944 cells were transfected with equal quantities of ERK1 siRNA and 
ERK2 siRNA for 48 h, and placed into fresh media for the indicated times up to an additional 72 h. The control consisted of NTC siRNA at the same 
total oligonucleotide concentration. Combined ERK1/2 knockdown led to 20–50% reduction in pERK1 levels and 50–75% reduction in pERK2 over 
the course of the 72 h. b The effect of combined ERK1/2 knockdown on H1944 cell proliferation was similar to that of ERK2 knockdown (Figure 4). 
Overall, the effects on growth were minimal except for a 13% decrease in proliferation of PTHrP-positive H1944 cells at 72 h. *P < 0.05 vs. control 
siRNA by paired t test.
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In addition, ectopic PTHrP production led to phospho-
rylation of ERK. The current study investigated the sign-
aling pathways involved in PTHrP-dependent growth 
inhibition.
PTH1R knockdown was employed to establish that the 
receptor had a role in limiting cell proliferation. Receptor 
knockdown abrogated the ability of exogenous PTHrP 
1–34 to inhibit H1944 cell proliferation and it also elimi-
nated the difference in growth rate between PTHrP-
positive and vector-transfected H1944 cell clones. The 
demonstration that PTH1R is necessary for ectopic 
PTHrP 1–87 to reduce lung cancer cell growth excludes 
a significant growth inhibitory role for mid-molecule 
PTHrP domains, i.e. PTHrP 38–87 or PTHrP 67–87. 
These peptides do inhibit proliferation in breast cancer 
cell lines (Luparello et al. 2001).
Gujral and colleagues evaluated interleukin-8 expres-
sion in prostate cancer cells transfected with PTHrP 
1–87 (Gujral et al. 2001), the same PTHrP form we stud-
ied. Ectopic PTHrP 1–87 significantly augmented IL-8 
levels, but treatment with exogenous PTHrP 1–34 and 
PTHrP 67–86 peptides did not. They suggested that 
PTHrP 1–87 was acting through an intracrine pathway, 
although nuclear effects seem unlikely in this instance 
since the peptide is missing the PTHrP nuclear localiza-
tion sequence found at residues 87–106 in the full length 
protein (Henderson et  al. 1995). In any case, our study 
establishes that ectopic PTHrP 1–87 inhibits H1944 cell 
proliferation at an extracellular site, based on the require-
ment for PTH1R. Thus, the mechanism involves cell sur-
face receptors, rather than intracrine pathways.
We have previously shown that PTH1R activation was 
coupled to Gs and generation of cAMP in H1944 cells 
and BEN lung cancer cells, rather than Gq pathways 
(Hastings et  al. 1996, 2004, 2009). When cell-permeant 
cAMP analogs were tested in this study, they mimicked 
the effect of PTHrP in inhibiting H1944 cell growth. 
Furthermore, the cAMP effects persisted in the face of 
PTH1R knockdown, as would be expected if cAMP acted 
as the downstream second messenger for PTH1R. We 
attempted to delineate the signaling pathways by com-
paring the effects of two cAMP analogs that differed in 
selectivity for either EPAC or PKA. Me-cAMP and phe-
cAMP both inhibited proliferation, suggesting either that 
EPAC and PKA independently inhibited cell proliferation 
or that they converged on a common inhibitory pathway.
PTHrP–PTH1R interactions have also been reported 
to cause cAMP-dependent growth arrest of vascular 
smooth muscle cells (Stuart et al. 2000). In smooth mus-
cle cells, the effects involve an increase in p27kip1, inhi-
bition of cyclin dependent kinase activity and reduction 
of Rb phosphorylation, similar to the effects of PTHrP in 
H1944 lung cancer cells (Hastings et al. 2009).
PTHrP and the cAMP analogs activated ERK in H1944 
cells (Figure 3a; Figure 7b in Hastings et  al. 2009). ERK 
activation could either contribute to growth inhibition or 
limit it depending on the direction of the ERK effect. The 
slower growth rate observed after either ERK2 knock-
down or combined ERK1/ERK2 knockdown suggests that 
the overall effect of ERK phosphorylation is to stimulate 
proliferation. PTHrP-induced ERK activation also has a 
pro-proliferative effect in oral squamous carcinoma cells, 
osteoblasts, and colon cancer cells (Yamada et  al. 2008; 
Datta et  al. 2007; Martin et  al. 2014). Our findings sug-
gest that ERK activation could limit the anti-mitogenic 
effect of PTHrP and cAMP in H1944 cells. However, the 
ERK proliferative effect is small, so ERK phosphorylation 
would be a weak mitogenic stimulus at best in H1944 
cells. The greatest effects of ERK knockdown occurred in 
PTHrP-positive cells, the cells where ERK phosphoryla-
tion was greatest.
Interpretation of the ERK1 knockdown experiments 
was complicated by a concomitant substantial increase 
in ERK2 expression. The increase in growth after ERK1 
knockdown could be most simply ascribed to a pro-
proliferative effect from the increase in ERK2. However, 
Figure 7 cAMP effects are independent of ERK. Wild type H1944 cells were transfected with oligonucleotides directed against ERK1 or against 
control, NTC sequences for 48 h as described in Figure 5. The transfected cells were replated and treated with media containing vehicle, 200 µM 
phe-cAMP or 200 µM me-cAMP and assayed for growth over 5 days. ERK1 knockdown had no effect on the growth inhibitory effects of the cAMP 
analogs. Inhibition for phe-cAMP amounted to 50–60% compared to vehicle and roughly 40% for me-cAMP. ‡P < 0.001. The graph on the right 
shows that the ERK1 siRNA reduced ERK1 expression by about 50%. **P < 0.01.
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we cannot rule out the possibility that ERK1 activation 
inhibits growth and that reduction in its activity had a 
direct effect to increase cell proliferation in addition to 
the indirect effect on ERK2. ERK1 knockdown did not 
have a substantive effect on the growth inhibitory action 
of the cAMP analogs, consistent with the proposal for 
a minimal role in regulating H1944 proliferation. The 
change in ERK2 levels with ERK1 knockdown was unex-
pected and suggests that the expression of one ERK iso-
form may regulate the other in lung cancer cells. The 
finding is novel as we know of no previous report of such 
a feedback arrangement.
Conclusions
In summary, this study explored two aspects of the 
upstream signaling mechanisms through which PTHrP 
regulates lung cancer cell proliferation. The first finding 
was that cell surface interactions of PTHrP 1–34 with 
PTH1R inhibit proliferation. The effect may be medi-
ated, in part, by cAMP as a second messenger. The sec-
ond major finding was that activation of ERK could not 
account for PTHrP-mediated growth inhibition. Instead, 
ERK2 phosphorylation led to modest stimulation of 
proliferation, while the effect of activated ERK1 was 
poorly defined. Thus, PTHrP-mediated growth inhibi-
tion would be somewhat larger if not for the action of 
ERK2. The finding that PTHrP interferes with lung can-
cer cell growth by binding to its cell-surface receptor, 
PTH1R, could have clinical implications. It is conceivable 
that synthetic ligands or small molecule drugs could be 
designed to activate PTH1R and inhibit lung carcinoma 
growth.
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